NCT03273699

Mindfulness Meditation Utilizing an EEG Biofeedback Device for the Treatment for Obsessive Compulsive Disorder

Completed NA Last updated 10 April 2019

What this trial tests

NA trial testing Mindfulness in Obsessive-Compulsive Disorder in 71 participants. Completed in 31 January 2019.

Timeline

10 April 2017

Primary endpoint
31 January 2019

31 January 2019

Quick facts

Lead sponsor	Sunnybrook Health Sciences Centre
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	71
Start date	10 April 2017
Primary completion	31 January 2019
Estimated completion	31 January 2019
Sites	1 location across Canada

Drugs / interventions tested

• Mindfulness

Conditions studied

• Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

Adults 18 to 60, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Frederick W. Thompson Anxiety Disorders Centre has experienced significant demand for services related to the treatment of Obsessive Compulsive Disorder (OCD), resulting in a significant wait time for service. Although Cognitive Behavior Therapy (CBT) is the most efficacious treatment intervention for OCD, there is a growing literature indicating the mindfulness based approaches can be beneficial in terms of managing acute mood and anxiety symptoms as well as reducing relapse risk following treatment.The goal of this study is to examine the potential benefits of using a consumer grade EEG-based biofeedback device that allows clients to engage in home based mindfulness meditation practices while they are waiting to receive clinical services. Specifically, this study will investigate the effects of meditation home practice on symptom alleviation, as related to specific OCD related cognitive processes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Obsessive-compulsive disorder.
   Stein DJ, Costa DLC, Lochner C, Miguel EC, et al · · 2019 · cited 495× · PMID 31371720 · DOI 10.1038/s41572-019-0102-3